Page 6 - Indian Pharma

Trump's focus on local drugs not immediate concern: Indian pharma industry

US is one of the major export destinations for drugmakers in India, accounting for roughly 33 per cent of the country's drug exports

Lincoln Pharma plans to foray into regulated markets, upgrades facility

The company has upgraded its manufacturing facility at Khatraj near Ahmedabad with Rs 30-crore investment

India scores better than US in regulatory action by USFDA in 2019

From FY15 to FY19, Indian manufacturers received fewer warning letters than Chinese counterparts

Prolonged coronavirus outbreak in China could hurt Indian pharma sector

China accounted for 67.56% of total imports of bulk drugs and drug intermediates in 2018-19 at $2,405.42 million.

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Indian pharma firms see fall in rate of final product approvals from USFDA

Analysts are optimistic that the sanction rate is likely to witness a pickup in the second half of the year.

Indian drug firms' growth slowed in 2017 on slow approvals, MNCs' caught up

GST rollout, more medicines being brought under price control, slow rate of drug approvals by NPPA hit Indian players, which control 80% of the domestic pharma market

Indian pharma should look beyond generics

Players need to step up investment in newer areas such as specialty drugs and biosimilars

Indian pharma lags on digital adoption: EY

Use of digital tools to gain customer insight, stakeholder engagement and disease management is limited

Indian pharma poised for US acquisitions

Mumbai, 7 AugustThe assets of Teva Pharmaceutical Industries have become acquisition targets following devastating results announced last week by the world's biggest maker of generic medicines.Teva's profits in the second quarter dropped to $1 billion from $1.23 billion a year earlier. Its stock slumped the most in almost two decades and the yield on its bonds jumped after the drugmaker warned that it might breach some debt covenants this year if sales did not rise.Soon, names of drug makers Fresenius, Mylan and Novartis started doing the rounds as buyers of some of Teva's assets, expected to be sold to repay debt.Teva's acquisition of Allergan's generic business last year for $40.5 billion has become troublesome as generic drugmakers' profit margins are being squeezed in the US, the world's biggest market. The Food and Drug Administration (FDA) is speeding up drug approvals, flooding the market with products from smaller companies that compete on price. It also came at a time when ...

Indian drug firms' R&D spending rises as growth slows in US, domestic mkts

Firms have spent around 9% of their operating income on research and development activities

Indian pharma's long road to redemption

IPA says its members need min 5 yrs to get manufacturing standards, data reliability up to scratch

Drugmakers need time to meet global standards: Indian Pharma Association

India's firms supply a third of the drugs sold in the US and a large percentage in other countries

Rising rupee another risk for Indian pharma

Pricing pressure and regulatory issues are not the only thing worrying executives of Indian pharmaceuticals' companies. Weakening of the dollar versus the rupee in the first four months of this calendar year is adding to the concerns; it might impact their earnings by five or six per cent. An appreciation in the rupee versus the dollar means every one of the latter yields less of the former, whereas a lot of the costs are denominated in rupees.Dr Reddy's Laboratories (DRL), Lupin and Sun Pharmaceutical earn close to half their revenue from the US market. DRL has the highest foreign exposure among large-cap stocks and earns 85 per cent of its revenue from abroad (53 per cent from North America); the rest is from India. Cipla, which earns 40 per cent of revenue from within India, would see the least impact from rupee appreciation; its US sales account for 18 per cent of the revenue. On a year-to-date basis (from January till this Thursday), the rupee has gained 5.45 per cent against ...

Quality culture: A big test for Indian pharma

Once a culture that fosters high standards is in place, the sector will truly become world class

Indian pharma pads up to fight Republican border tax

Experts claim border adjustment tax would hurt profits, increase healthcare costs

Changes in US put Indian pharma's R&D to test

With medicines going off patent over next 3 yrs, pharma majors have stepped up spending on research

Pricing pressure in US to take sheen off pharma

Torrent, Dr Reddy's, and Sun Pharmaceutical could see higher price erosion of existing portfolio